Amycretin
Also called Zenagamtide, NNC0487-0111.
Amycretin is still investigational, with no FDA-approved product. This page cites 2 sources, and the strongest evidence comes from human trials.
- Status
- Investigational
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
The subcutaneous cohort of a 36-week phase 2 trial found greater HbA1c reductions with weekly zenagamtide than placebo in adults with type 2 diabetes taking metformin, with or without an SGLT2 inhibitor.
Limits: This cohort randomized 262 participants across multiple groups. The primary analysis used on-treatment data without rescue medication. It does not establish long-term cardiovascular outcomes or a head-to-head comparison with the oral formulation.
Human trials
The oral cohort of the same 36-week phase 2 trial found greater HbA1c reductions with daily oral zenagamtide than placebo in adults with type 2 diabetes.
Limits: This cohort randomized 186 participants and reported gastrointestinal adverse events. The oral and subcutaneous papers share NCT06542874 and count as one study. Separate cohort findings do not establish equal efficacy or interchangeable administration between oral and injected forms.
Regulatory status
United States
Novo Nordisk now calls amycretin zenagamtide. It remains investigational, with no FDA-approved product identified as of November 6, 2026. Novo reports phase 3 programs for subcutaneous and oral formulations, including the oral AMAZE 9 study initiated in September 2026.